Payment overview · 2025
General Payments
$2,556.47
123 reported records · 25 companies
Healthcare provider profile · identity verified
Michael Tavdy, M.D.
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1720016793
Verified facts
What the public records show
CMS Open Payments records show Michael Tavdy, M.D. received $2,556.47 in general payments during 2025 across 123 reported records.
ABBVIE INC. accounted for 10.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Veozah, Xifaxan, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 905 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EUCRISA as an associated drug or biological on 1712 records involving 991 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eucrisa by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.39 | 10.8% | 15 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $243.88 | 9.5% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $223.11 | 8.7% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $189.89 | 7.4% | 7 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $171.10 | 6.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.50 | 6.5% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $154.19 | 6.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.76 | 5.9% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $139.14 | 5.4% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $127.73 | 5.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.94 | 4.8% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.33 | 3.4% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $78.75 | 3.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.37 | 2.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $59.02 | 2.3% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $50.00 | 2.0% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $45.88 | 1.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $31.99 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.42 | 1.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.75 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.95 | 0.9% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $21.87 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.77 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.50 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.24 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,486.48 | 122 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $223.12 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $213.34 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $200.22 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $189.89 | 7 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $171.10 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $154.19 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $153.12 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $139.14 | 9 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $127.73 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $123.94 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $118.77 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $102.18 | 7 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $87.33 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $78.75 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.37 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $59.02 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $58.26 | 5 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.58 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $43.66 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 276 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 275 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 425 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 210 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 57 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 262 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 355 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
276 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
425 | 57 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
905 | 105 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
262 | 38 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 32 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
243 | 32 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
425 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
210 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | EUCRISA open payments reported associated product |
CMS Open Payments — General Payments 1712 supporting records · 991 recipient NPIs · example record 1228794851 |
Eucrisa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
355 | 59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1143 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 979 | 141 |
| Synthroid | Levothyroxine Sodium | 905 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 815 | 104 |
| Diclofenac Sodium | Diclofenac Sodium | 751 | 119 |
| Vascepa | Icosapent Ethyl | 611 | 86 |
| Gabapentin | Gabapentin | 595 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 574 | 73 |
| Memantine Hcl | Memantine Hcl | 565 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 553 | 72 |
| Omeprazole | Omeprazole | 537 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 446 | 49 |
| Linzess | Linaclotide | 425 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 421 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 420 | 60 |
| Furosemide | Furosemide | 388 | 71 |
| Meclizine Hcl | Meclizine Hcl | 368 | 57 |
| Ztlido | Lidocaine | 355 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 350 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 320 | 71 |
| Dexlansoprazole Dr | Dexlansoprazole | 317 | 44 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 287 | 43 |
| Dexilant | Dexlansoprazole | 283 | 34 |
| Lisinopril | Lisinopril | 279 | 37 |
| Creon | Lipase/Protease/Amylase | 276 | 40 |
| Eliquis | Apixaban | 275 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 275 | 51 |
| Zenpep | Lipase/Protease/Amylase | 262 | 38 |
| Carvedilol | Carvedilol | 256 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 251 | 41 |
| Ammonium Lactate | Ammonium Lactate | 250 | 46 |
| Myrbetriq | Mirabegron | 243 | 32 |
| Glimepiride | Glimepiride | 241 | 33 |
| Losartan Potassium | Losartan Potassium | 239 | 35 |
| Ibuprofen | Ibuprofen | 236 | 54 |
| Donepezil Hcl | Donepezil Hcl | 228 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 43 |
| Labetalol Hcl | Labetalol Hcl | 219 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 37 |
| Metformin Hcl | Metformin Hcl | 211 | 36 |
| Mounjaro | Tirzepatide | 210 | 29 |
| Tradjenta | Linagliptin | 210 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 207 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 200 | 29 |
| Sertraline Hcl | Sertraline Hcl | 189 | 33 |
| Icosapent Ethyl | Icosapent Ethyl | 187 | 29 |
| Meloxicam | Meloxicam | 184 | 40 |
| Memantine Hcl Er | Memantine Hcl | 182 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 179 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 178 | 35 |
| Doxepin Hcl | Doxepin Hcl | 176 | 34 |
| Naproxen | Naproxen | 176 | 30 |
| Famotidine | Famotidine | 164 | 25 |
| Simvastatin | Simvastatin | 163 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 158 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 152 | 29 |
| Entresto | Sacubitril/Valsartan | 146 | 20 |
| Januvia | Sitagliptin Phosphate | 144 | 20 |
| Xarelto | Rivaroxaban | 141 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 140 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 139 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 21 |
| Montelukast Sodium | Montelukast Sodium | 137 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 134 | 32 |
| Enalapril Maleate | Enalapril Maleate | 131 | 21 |
| Ezetimibe | Ezetimibe | 130 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 22 |
| Lidocaine | Lidocaine | 122 | 20 |
| Ramipril | Ramipril | 120 | 11 |
| Valsartan | Valsartan | 117 | 19 |
| Ozempic | Semaglutide | 116 | 19 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 115 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 112 | 46 |
| Hydrocortisone | Hydrocortisone | 106 | 22 |
| Jardiance | Empagliflozin | 106 | 14 |
| Nitroglycerin | Nitroglycerin | 106 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 13 |
| Celecoxib | Celecoxib | 90 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 90 | 13 |
| Gemtesa | Vibegron | 89 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 12 |
| Ketoconazole | Ketoconazole | 86 | 14 |
| Atenolol | Atenolol | 84 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 84 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 11 |
| Benicar | Olmesartan Medoxomil | 79 | suppressed |
| Allopurinol | Allopurinol | 76 | 11 |
| Dutasteride | Dutasteride | 76 | suppressed |
| Mupirocin | Mupirocin | 76 | 17 |
| Telmisartan | Telmisartan | 76 | suppressed |
| Rivastigmine | Rivastigmine | 74 | 12 |
| Finasteride | Finasteride | 73 | 12 |
| Azithromycin | Azithromycin | 72 | 56 |
| Crestor | Rosuvastatin Calcium | 70 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 13 |
| Nexium | Esomeprazole Magnesium | 70 | 12 |
| Risperidone | Risperidone | 70 | 11 |
| Clonidine Hcl | Clonidine Hcl | 68 | 19 |
| Ranolazine Er | Ranolazine | 68 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 68 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 13 |
| Trulance | Plecanatide | 66 | 15 |
| Alendronate Sodium | Alendronate Sodium | 65 | suppressed |
| Colchicine | Colchicine | 65 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 11 |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 59 | suppressed |
| Methimazole | Methimazole | 57 | suppressed |
| Prolia | Denosumab | 57 | 32 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 56 | suppressed |
| Clotrimazole | Clotrimazole | 54 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 18 |
| Edarbi | Azilsartan Medoxomil | 50 | suppressed |
| Procto-Med Hc | Hydrocortisone | 50 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 49 | suppressed |
| Folic Acid | Folic Acid | 49 | suppressed |
| Lubiprostone | Lubiprostone | 49 | suppressed |
| Nystatin | Nystatin | 49 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 13 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 47 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Cilostazol | Cilostazol | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Livalo | Pitavastatin Calcium | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 31 |
| Acyclovir | Acyclovir | 39 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 11 |
| Proctozone-Hc | Hydrocortisone | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Bystolic | Nebivolol Hcl | 35 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Mesalamine | Mesalamine | 33 | suppressed |
| Metolazone | Metolazone | 33 | 11 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Cyclosporine | Cyclosporine | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Silodosin | Silodosin | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Restasis | Cyclosporine | 26 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Nyamyc | Nystatin | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Ssd | Silver Sulfadiazine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | suppressed |
| Veozah | Fezolinetant | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lialda | Mesalamine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 13 | suppressed |
| Unithroid | Levothyroxine Sodium | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 12 | suppressed |
| Avodart | Dutasteride | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Eucrisa | Crisaborole | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,556.47 · 123 records | ABBVIE INC. | ACCRUFER, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, IBSRELA, Kerendia, Korlym, LINZESS, Leqembi, MAVYRET, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PANCREAZE, PROLIA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, Veozah, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND, ZORYVE, ZTLido, ZURZUVAE | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error